Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of oral levosimendan in ALS after REFALS
NL-OMON49083Phase 3Completed
- Sponsor
- Orion Corporation
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of levosimendan, sponsored by Orion Corporation. Started Nov 2019; status: completed.
02
Drugs
levosimendan
Beyond the preview
Go deeper on NL-OMON49083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49083.